HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 1651-1662

  Cao, Manqing ^a   Gao, Junrong ^a   Zhou, Hongyuan ^a   Huang, Jiafei ^a   You, Abin ^a   Guo, Zhigui ^a   Fang, Feng ^a   Zhang, Wei ^a   Song, Tianqiang ^a   Zhang, Ti ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CDCP1; Hepatocellular carcinoma; HIF 2 ; Metastasis; PKC

Indexed keywords

CUB DOMAIN CONTAINING PROTEIN 1; GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROTEIN KINASE C DELTA; PROTEIN TYROSINE KINASE; TYROSINE; UNCLASSIFIED DRUG; ACETYLCYSTEINE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; LEUKOCYTE ANTIGEN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL MOTION; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ACETYLCYSTEINE; ANIMALS; ANTIGENS, CD; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; PROTEIN KINASE C-DELTA; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84940201568     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3527-7     Document Type: Article

References (38)

1. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009;107(6):1053–62. doi:10.1002/jcb.22214.
2. Silvan U, Diez-Torre A, Arluzea J, Andrade R, Silio M, Arechaga J. Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology. Differ; Res Biol Divers. 2009;78(2–3):159–68. doi:10.1016/j.diff.2009.06.002.
3. Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, et al. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology. 2010;51(6):2183–92. doi:10.1002/hep.23597.
4. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl Immunohistochem Molec Morphol: AIMM / Off Public Soc Appl Immunohistochem. 2006;14(1):78–82. doi:10.1097/01.pai.0000145182.98577.10.
5. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 2002;62(5):1326–9.
6. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006;10(5):413–23. doi:10.1016/j.ccr.2006.08.026.
7. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol. 2006;26(9):3514–26. doi:10.1128/MCB.26.9.3514-3526.2006.
8. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85(6):881–90. doi:10.1054/bjoc.2001.2018.
9. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675–86. doi:10.1128/MCB.25.13.5675-5686.2005.
10. Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012;72(9):2285–93. doi:10.1158/0008-5472.CAN-11-3836.
11. Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, et al. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 2013;57(3):1088–97. doi:10.1002/hep.26188.
12. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol: WJG. 2007;13(23):3176–82.
13. Bangoura G, Yang LY, Huang GW, Wang W. Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol: WJG. 2004;10(4):525–30.
14. Liu Y, Yan X, Xu Y, Luo F, Ye J, Yan H, et al. HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35(8):8103–14. doi:10.1007/s13277-014-2056-0.
15. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203. doi:10.1016/j.cell.2007.11.025.
16. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001;20(32):4402–8.
17. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol. 2008;134(12):1363–9. doi:10.1007/s00432-008-0412-4.
18. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A. 2011;108(5):1931–6. doi:10.1073/pnas.1011777108.
19. Seidel J, Kunc K, Possinger K, Jehn C, Luftner D. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochem Biophys Res Commun. 2011;414(1):226–32. doi:10.1016/j.bbrc.2011.09.062.
20. Perry SE, Robinson P, Melcher A, Quirke P, Buhring HJ, Cook GP, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. 2007;581(6):1137–42. doi:10.1016/j.febslet.2007.02.025.
21. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010;70(12):5136–46. doi:10.1158/0008-5472.CAN-10-0220.
22. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci U S A. 2011;108(4):1379–84. doi:10.1073/pnas.1017228108.
23. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 2007;27(21):7649–60. doi:10.1128/MCB.01246-07.
24. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 2009;100(3):429–33. doi:10.1111/j.1349-7006.2008.01066.x.
25. Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, et al. Identification of CDCP1 as a hypoxia-inducible factor 2alpha (HIF-2alpha) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2013;110(9):3483–8. doi:10.1073/pnas.1222435110.
26. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005;121(2):271–80. doi:10.1016/j.cell.2005.02.019.
27. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol. 2008;172(6):1729–39. doi:10.2353/ajpath.2008.070981.
28. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol: WJG. 2001;7(5):630–6.
29. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem. 2012;287(13):9792–803. doi:10.1074/jbc.M111.335448.
30. Befani C, Mylonis I, Gkotinakou IM, Georgoulias P, Hu CJ, Simos G, et al. Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells. Int J Biochem Cell Biol. 2013;45(11):2359–68. doi:10.1016/j.biocel.2013.07.025.
31. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, et al. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem. 2010;285(34):26162–73. doi:10.1074/jbc.M109.096453.
32. Brenner W, Greber I, Gudejko-Thiel J, Beitz S, Schneider E, Walenta S, et al. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase. Int J Oncol. 2008;32(5):1125–31.
33. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene. 2003;22(12):1783–94. doi:10.1038/sj.onc.1206220.
34. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9–22. doi:10.1038/nrc3183.
35. Wu XH, Qian C, Yuan K. Correlations of hypoxia-inducible factor-1alpha/hypoxia-inducible factor-2alpha expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J. 2011;124(1):11–8.
36. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, et al. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008;68(22):9212–20. doi:10.1158/0008-5472.CAN-08-1135.
37. Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, et al. HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(23):7130–6. doi:10.1158/1078-0432.CCR-09-0223.
38. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007;11(4):335–47. doi:10.1016/j.ccr.2007.02.006.